Kodama K, Ghanta V K, Hiramoto R N, Stohrer R C, Kearney J F
Cancer Res. 1986 Mar;46(3):1250-4.
We investigated the effect of three monoclonal anti-idiotype antibodies (anti-M104E) on various functions of MOPC 104E myeloma cells in vitro. The antibodies used were N-20-2 [immunoglobulin M (IgM), BALB/c], SJL18-1 [IgM, BALB/c X SJL F1], and CD3-2 [immunoglobulin G1 (IgG1), BALB/c X A/J F1]. The two IgM antibodies were very efficient in blocking surface M104E IgM as shown by rosette inhibition, whereas the IgG1 isotype was not very effective. The reexpression of surface M104E IgM was different from antibody to antibody. The secretion of M104E IgM by MOPC 104E cells was partially blocked by the two IgM antibodies, but the IgG1 antibody had no effect. All three anti-idiotype antibodies inhibited the stem cell renewal activity of MOPC 104E cells assayed by colony formation assay. On the other hand, in suspension culture, the two IgM antibodies inhibited the growth of MOPC 104E cells in the absence of complement or effector cells of antibody-dependent cellular cytotoxicity, but IgG1 antibody had no effect. The starting tumor inoculum size was critical in the observations of the effects seen on both the growth and the colony-forming activity of MOPC 104E cells. The results of this study show the functional differences between various monoclonal anti-idiotype antibodies and also indicate that some anti-idiotype antibodies can inhibit the growth of MOPC 104E myeloma cells directly without any help of complement or effector cells of antibody-dependent cellular cytotoxicity.
我们在体外研究了三种单克隆抗独特型抗体（抗-M104E）对MOPC 104E骨髓瘤细胞各种功能的影响。所用抗体分别为N-20-2[免疫球蛋白M（IgM），BALB/c]、SJL18-1[IgM，BALB/c×SJL F1]和CD3-2[免疫球蛋白G1（IgG1），BALB/c×A/J F1]。如玫瑰花结抑制试验所示，两种IgM抗体在阻断表面M104E IgM方面非常有效，而IgG1同种型则效果不佳。表面M104E IgM的重新表达因抗体而异。MOPC 104E细胞分泌M104E IgM被两种IgM抗体部分阻断，但IgG1抗体无作用。通过集落形成试验测定，所有三种抗独特型抗体均抑制MOPC 104E细胞的干细胞更新活性。另一方面，在悬浮培养中，两种IgM抗体在无补体或抗体依赖性细胞毒性效应细胞的情况下抑制MOPC 104E细胞的生长，但IgG1抗体无作用。起始肿瘤接种量对观察MOPC 104E细胞生长和集落形成活性的影响至关重要。本研究结果显示了各种单克隆抗独特型抗体之间的功能差异，也表明某些抗独特型抗体可直接抑制MOPC 104E骨髓瘤细胞的生长，而无需补体或抗体依赖性细胞毒性效应细胞的任何帮助。
